Intensity Therapeutics in the News

Killing Cancer Through Direct Injection

Intensity Therapeutics founder and the inventor of Intensity’s DfuseRx platform technology, Lew Bender, discusses the technology that allows the company’s therapeutic products to be injected directly into solid tumors. This innovative process successfully kills tumors and activates an immune response to shut down cancer cells throughout the body.

read more

BioBoss Interview of Intensity’s CEO Lewis H. Bender

BioBoss host John Simboli interviewed Intensity Therapeutics’ CEO, Lewis H. Bender in March of 2020. The two discussed the challenges facing a small company developing a unique approach to treating cancer, leadership, partnerships, the potential benefits of the new therapy and the risks & fears that entrepreneurs face when starting a biotech company.

read more

Clinical Leader: How One Small Biotech is Changing the Fight Against Cancer

Intensity Therapeutics would like to change the way cancer patients are treated. Treatments such as chemotherapy and radiation impact a patient’s entire body, administering toxic side-effects throughout their system.

read more

Combining Local & Systemic Treatments: Could Immuno-Oncology Finally Enable Local Intratumoral Delivery?

In an interview with Drug Development and Delivery, Lewis H. Bender, MA, MBA, says cancer is a local and systemic disease, and new forms of local treatment, such as intratumoral dosing coupled with systemic immunotherapy, are being explored.

read more

Lewis Bender Started a Company to Cure Cancer

Lewis Bender, CEO of a Connecticut startup called Intensity Therapeutics, feels compelled to cure cancer. “I had friends dying of cancer when I was in my 50s,” Bender said. “I had an idea…”

read more

PharmaVOICE Names Intensity Therapeutics’ CEO, Lewis H. Bender, One of 100 Most Inspiring People for 2019

[pdf-embedder url=”https://intensitytherapeutics.com/wp-content/uploads/2019/08/PharmaVOICE-finished-article.pdf” title=”PharmaVOICE finished …

read more

ForbesBooks Radio: Lewis H. Bender, Founder/CEO, talks Intensity Therapeutics

Starting in his basement, Lew and his team have created unique cancer penetrating drugs that kill tumors and boost immunity via direct injection, with minimal side effects.

read more

A Treat Locally, Act Globally Strategy for Treating Cancer

Intensity is developing cancer therapies that are delivered directly into tumors, but also stimulate the innate immune system to address the more systemic effects of cancer. We spoke to Lewis Bender, CEO of Intensity, about the company’s platform technology, how it enlists the innate immune system in the battle against cancer, and the thinking behind the company’s approach.

read more

Tuning In: Intensity’s immune-based chemo delivery tech attracts backing of British billionaire Jim Mellon

In cancer treatment, chemotherapy and immunotherapy are often seen as completely separate, if complementary, categories of treatments. A tiny biotech out of Westport, CT now wants to shake up that paradigm — and has just raised $6.5 million to do so.

read more

Westport Biotech Venture Aims to Make a Cancer Cure that Lasts

A Westport biotechnology company is looking to redefine what it means to be cured of cancer, developing a treatment that essentially trains the immune system to recognize diseased cells and fight back any recurrence. Intensity Therapeutics began clinical trials this year to test the safety of its treatment, an injection of a drug called INT230-6 directly into a tumor.

read more

Westport’s Intensity Therapeutics optimistic about potential cancer treatment

Westport’s Intensity Therapeutics gains ground with potential game changing cancer treatment. Armed with a pair of U.S. patents and some $13 million in investments, Intensity Therapeutics Inc. in Westport has started clinical trials on what its founder maintains could be a game-changer in the treatment of cancer.

read more

Intensity Therapeutics Begins Human Testing of Intratumoral Cancer Drug

Intensity Therapeutics said today that the 1st patient was treated in a Phase I/II trial of its intratumorally-administered cancer therapy, INT230-6. The company’s plans to evaluate the safety of its cancer-killing agent in patients with tumors that are treated at the surface of the skin, including breast cancer and melanoma.

read more

Intensity Therapeutics Inc. – Delivering Improved Immunotherapy

Intensity Therapeutics Inc. got its start when Lewis H. Bender, then the CEO of Interleukin Genetics Inc., pondered the treatment failures in checkpoint inhibitors. “I thought, ‘There’s a steering wheel missing,’” he recalls. The key would be to kill tumor cells, but in a way that left them and their cell surface proteins more or less intact.

read more

Throwing Cancer a One-Two Combo

Many cancer treatments have achieved cures in mice only to fail in humans. Intensity Therapeutics has studied these failed challengers, and it may have learned why they failed to go the distance.

read more

Chicago venture investor Batterson eyes crowdfunding for cancer treatment

Venture investor Len Batterson says new crowdfunding rules will widen the pool of sophisticated investors, too.

read more

Intensity Therapeutics Looks to Raise USD 7.5m to Bring Intratumoral Chemo to Clinical Trials

Intensity Therapeutics has raised USD 1.5m of its planned USD 9m target for its lead preclinical candidate, an intratumoral chemotherapy, said CEO Lewis Bender. By the end of 3Q14, the firm plans to finalize CMOs and CROs for clinical studies, he noted.

read more

Intensity: More with Less

Intensity Therapeutics Inc. is developing what could become the first intratumoral chemotherapeutics to achieve better efficacy than systemic chemo by using a formulation technology that enables passive diffusion into tumor cells.

read more